Roche Diagnostics Signs New Investment Project in Suzhou!

Recently, Roche Diagnostics Suzhou signed an agreement for a new investment project with the Suzhou Industrial Area Administrative Committee. The signing ceremony was attended by Swiss Ambassador to China Bernardino Regazzoni, Mayor of Suzhou Wu Qingwen, Global Head of Roche Diagnostics Operations Kent Kost, Head of Roche Diagnostics Asia Pacific Lance Little, General Manager of Roche Diagnostics Asia Pacific Production Base and R&D Center Marco Cairoli, General Manager of Roche Diagnostics China Yao Guoliang, and President of Roche Pharmaceuticals China Bian Xin.

The first phase of this new project involves an investment of 3 billion CNY, covering an area of 55 mu (about 36,667 square meters), with a planned construction area of approximately 60,000 square meters. The project is expected to be operational by 2028. This investment will be used for the construction of new facilities for the production and R&D of Roche diagnostic reagents and instrument equipment, as well as the localization of key product manufacturing, further increasing the company's investment in the Chinese market. 

Snibe H1 Net Profit Rise 20.42%

On August 22, Snibe Released Its 2024 Semi-Annual Report that the company achieved operating revenue of 2.211 billion CNY, a year-on-year increase of 18.54%, and a net profit attributable to shareholders of 903 million CNY, a year-on-year increase of 20.42%. 

 

As of now, the company has obtained registration for 181 chemiluminescence reagents in the domestic market (with a total of 257 registration certificates). The supporting reagents cover a wide range of tests, including tumor markers, thyroid, infectious diseases, gonads, cardiac markers, inflammation monitoring, glucose metabolism, bone metabolism, liver fibrosis, and autoimmune antibodies. In the actively expanding biochemical diagnostics product line, snibe sells five fully automated biochemical analyzers and 61 supporting reagents globally. Among them, 61 biochemical reagents (with a total of 92 registration certificates) have been registered domestically, covering tests for kidney function, liver function, specialty proteins, lipids, and more.

Autobio Reports 620 Million CNY Net Profit for the First Half of 2024

On August 20th, Autobio released its semi-annual report. In the first half of 2024, the company achieved operating revenue of 2.207 billion CNY, a year-on-year increase of 4.70%, and a net profit attributable to shareholders of 620 million CNY, a year-on-year increase of 13.49%.

 

In terms of innovation, the company continuously increased its R&D investment and actively explored new fields and developed new products in the first half of 2024, with some projects already showing promising results. During the reporting period, R&D investment amounted to 333.23 million CNY, accounting for 15.10% of operating revenue. From 2021 to 2023, R&D investment was 485.95 million CNY, 571.69 million yuan, and 656.13 million CNY, accounting for 12.90%, 12.87%, and 14.77% of operating revenue, respectively.

Geneseeq and MGI Forge Global Strategic Partnership

Recently, Geneseeq and MGI launch project to collaborate on Large-Scale Natural Population Tumor Early Screening Projects, which will leverage their complementary technological strengths to jointly advance breakthroughs in the clinical translation of high-throughput sequencing technology for oncology.

 

Previously, Geneseeq has developed oncology-related products using MGI's sequencing platforms, including the DNBSEQ-G99, DNBSEQ-T7, and MGISEQ-2000. Moving forward, the partnership will focus on key areas such as clinical foundational research, instrument and reagent registration and certification, clinical application and promotion, precision oncology, and early cancer screening and diagnosis. These efforts will be supported by MGI's gene sequencing platforms, laboratory automation platforms, and information management platforms, establishing an innovative foundation for precision oncology.